Li Zai Xin, Hu Wei Dong, Li Bing Chao, Li Tian You, Zhou Xiao Yang, Zhang Zhi
Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China.
Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China.
Vet Immunol Immunopathol. 2014 Jan 15;157(1-2):97-104. doi: 10.1016/j.vetimm.2013.10.002. Epub 2013 Oct 30.
VP60 capsid protein is the major structural and immunogenicity protein of RHDV (Rabbit hemorrhagic disease virus, RHDV), and has been implicated as a main protein antigen in RHDV diagnosis and vaccine design. In this report, egg yolk antibody (IgY) against N-terminal of VP60 was evaluated and developed as a new strategy for RHDV therapy. Briefly, N-terminal of VP60 (∼250aa) fragment was cloned and inserted into pET28a expression vector, and then the resultant plasmid, pET28a/VP60-N, was transformed into E. coli BL21(DE3) for recombinant VP60-N protein (rVP60-N) expression. Next, the rVP60-N was purified by Ni(+)-affinity purification chromatography and identified by Western blotting with RHDV antiserum. After immunizing the chickens with rVP60-N, the anti-rVP60-N IgY was isolated, and the activity and specificity of the IgY antibody were analyzed by ELISA and Western blotting. In our results, the rVP60-N could be expressed in E. coli as soluble fraction, and the isolated anti-rVP60-N IgY demonstrated a high specificity and titer (1:22,000) against rVP60-N antigen. For further evaluation of the IgY efficacy in vivo, rabbits were grouped randomly and challenged with RHDV, and the results showed that anti-rVP60-N IgY could significantly protect rabbits from virus infection and promote the host survival after a sustained treatment with anti-rVP60-N IgY for 5 days. Taken together, our study demonstrates evidence that production of IgY against VP60 could be as a novel strategy for the RHDV therapy.
VP60衣壳蛋白是兔出血症病毒(RHDV)的主要结构和免疫原性蛋白,并且在RHDV诊断和疫苗设计中被认为是主要的蛋白抗原。在本报告中,针对VP60 N端的蛋黄抗体(IgY)被评估并开发为一种新的RHDV治疗策略。简要地说,将VP60的N端(约250个氨基酸)片段克隆并插入pET28a表达载体,然后将所得质粒pET28a/VP60-N转化到大肠杆菌BL21(DE3)中以表达重组VP60-N蛋白(rVP60-N)。接下来,通过镍离子亲和纯化层析法纯化rVP60-N,并用RHDV抗血清进行Western印迹鉴定。用rVP60-N免疫鸡后,分离出抗rVP60-N IgY,并通过ELISA和Western印迹分析IgY抗体的活性和特异性。在我们的结果中,rVP60-N能够在大肠杆菌中以可溶性部分表达,并且分离出的抗rVP60-N IgY对rVP60-N抗原表现出高特异性和效价(1:22,000)。为了进一步评估IgY在体内的疗效,将兔子随机分组并用RHDV攻击,结果表明抗rVP60-N IgY能够显著保护兔子免受病毒感染,并在连续用抗rVP60-N IgY治疗5天后促进宿主存活。综上所述,我们的研究证明针对VP60产生IgY可作为RHDV治疗的一种新策略。